Replies to post #187217 on Biotech Values

[DewDiligence]

Merck KGaA sells FoB business to FRE.DE:

http://news.emdgroup.com/N/0/327E1F6634B69914C125810C005A3048/$File/PR_Biosimilars_24042017_US.pdf

Merck KGaA, Darmstadt…today announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with the company’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines.

According to the terms agreed for the transaction, Merck KGaA, Darmstadt, Germany will receive an upfront payment of €170 million, milestone payments of up to €500 million, plus royalties on future product sales.